Study of Patients With Chronic Hepatitis C Infected With HCV LVL G1 and Effect of Peg-Intron Plus Rebetol Treatment (Study P04793)
Study of Patients With Chronic Hepatitis C Infected With HCV LVL G1 and Effect of Peg-Intron Plus Rebetol Treatment (Study P04793)
To determine the relapse rate at 24 weeks follow up in Hepatitis C Virus Genotype 1 Low Viral
 Load (HCV LVL G1) patients treated for 24 weeks with Peg Intron and Rebetol who are Hepatitis
 C Virus-Ribonucleic Acid (HCV-RNA) negative at treatment week 4 and week 24. To determine the
 proportion of patients (%) with sustained virological response at 24 weeks post follow up
 treatment.
Approximately 500 patients from about 100 sites to be identified as HCV LVL G1 patients
Inclusion Criteria:

 -  Willingness to participate

 -  18 years or older, either gender, any race

 -  Must have Hepatitic C Virus Low Viral Load [LCV LVL] (positive, but <600,000 IU/mL on
 the assay used by the individual study site. Only Hepatitis C Virus-Ribonucleic
 acid/quantitative polymerase chain reaction [HCV-RNA/qPCR] assays with results in
 IU/ml are acceptable) AND been diagnosed with Genotype 1

 -  Subject considered suitable for treatment per local label

 -  Investigator considers suitable and subject consents to be treated

 Exclusion Criteria:

 -  Does not show negative polymerase chain reaction [PCR] at week 4

 -  Pregnant women or those who plan to become pregnant or sexual partners of women who
 plan to become pregnant

 -  Subject does not qualify based on contra-indication, special warning, special
 population, and/or pregnancy & lactation section of the Summary of Product
 Characteristics [SmPC]